<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729778</url>
  </required_header>
  <id_info>
    <org_study_id>16-1919</org_study_id>
    <nct_id>NCT03729778</nct_id>
  </id_info>
  <brief_title>Impact of HIV-1 and Aging on Mucosal Vaccine Responses</brief_title>
  <official_title>Impact of HIV-1 and Aging on Mucosal Vaccine Responses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Eastern Colorado Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Eastern Colorado Health Care System</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn more about both HIV-1 infection and advancing age,
      alone and in combination, and their association with increased risk of serious infection and
      impaired response to the Prevnar 13 vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine pneumococcal specific IgG levels in BAL (BronchoAlveolar Lavage) fluid and NPF (Nasopharyngeal Fluid)</measure>
    <time_frame>A change from baseline, measured at pre-vaccination, and 1 month post vaccine</time_frame>
    <description>Determine pneumococcal specific IgG levels in BAL fluid and NPF and to standardize the results we will compare it to the total levels in the BAL/NPF fluid collected at all timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine pneumococcal specific IgG levels in serum</measure>
    <time_frame>A change from baseline, measured at pre-vaccination, and 1 month post vaccine</time_frame>
    <description>Determine pneumococcal specific IgG levels in serum 1 month post vaccination response criteria must meet &gt;2-fold rise with a post-vaccination level &gt;1000 ng/ml for &gt; 7 of the 12 serotypes</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV-1-infection</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>HIV/AIDS</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>HIV+</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One time administration of Prevnar-13 vaccine to HIV+ participants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV Negative Controls</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One time administration of Prevnar-13 vaccine to HIV Negative Control participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar-13</intervention_name>
    <description>One time administration of prevnar-13 vaccine</description>
    <arm_group_label>HIV Negative Controls</arm_group_label>
    <arm_group_label>HIV+</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Veterans only (accessibility to non-veterans pending)

          -  Age 21-45 or 55-75 Years Old

          -  Have not received pneumococcal vaccine Prevnar PCV-13

          -  Able to attend 2-3 study visits over 1 month

        HIV+:

        -Undetectable Viral load

        HIV negative controls:

        -no history or risks for HIV infection

        Exclusion Criteria:

          -  Spleen removed

          -  Chronic Kidney disease (creatinine â‰¥ 2.0 mg/dL)

          -  Lymphoma or leukemia

          -  Currently taking: Corticosteroids (prednisone, medrol, etc), Chemotherapy,
             Immunosuppressive medication (cyclosporine, methotrexate, azathioprine, infliximab,
             adalimumab, rituximab, etanercept, etc), or illicit drugs (methamphetamine, cocaine,
             crack, or heroin)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mandy N Borgeson</last_name>
    <phone>720-788-8318</phone>
    <email>mandy.borgeson@cuanschutz.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy Rahkola</last_name>
    <phone>3037243020</phone>
    <email>Jeremy.Rahkola@cuanschutz.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rocky Mountain Regional VA Medical Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandy N Borgeson</last_name>
      <phone>720-788-8318</phone>
      <email>mandy.borgeson@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Edward N Janoff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 16, 2018</study_first_submitted>
  <study_first_submitted_qc>October 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Streptococcus pneumoniae infection</keyword>
  <keyword>Prevnar-13</keyword>
  <keyword>PCV-13</keyword>
  <keyword>Pneumococcal vaccine</keyword>
  <keyword>Pneumococcal vaccines</keyword>
  <keyword>Streptococcus pneumoniae colonization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

